ACADIA Pharmaceuticals enters the back half of September with short interest climbing sharply back toward levels that dominated the stock through most of August, even as the borrow market remains extraordinarily loose — a split that sets up an interesting read on how aggressive the bears really are.
The most notable move this week is in short interest itself. Shares short jumped roughly 14% in a single session on September 10, pushing SI back to 5.7% of the free float — a sharp reversal after weeks of steady covering that had unwound a position north of 11 million shares in mid-August down to the 8.5 million range. That one-day rebuild adds back more than 1.1 million borrowed shares in a name trading around $27.83, which closed the week down just under 1%. The borrow market tells a permissive story alongside that jump: availability is running at over 3,700% — meaning there are roughly 37 shares available to lend for every one currently borrowed — and cost to borrow is barely above zero at 0.46%. Anyone wanting to build a short position faces essentially no friction in the lending market.
Options positioning has shifted in the same cautious direction, though from a low base. The put/call ratio has drifted up to 0.40, above its 20-day average of 0.33 by about 1.4 standard deviations — elevated relative to recent norms, though still well below the 52-week high of 1.02 set earlier in the year. The move is more "quietly hedging" than "aggressively bearish." Taken together with the SI rebuild, the picture is one of bears returning to a position they had been steadily covering, rather than a fresh wave of conviction selling.
The Street, meanwhile, remains constructively positioned. Nearly every analyst action since the August 4 earnings print has been a target raise: Deutsche Bank moved to $38, Citigroup to $40, UBS to $49, Needham to $41, and RBC to $37 — all maintaining positive ratings. Morgan Stanley kept its Equal-Weight and nudged its target to $28, the lone cautious voice in a chorus of upgrades. The consensus mean target of $34 implies roughly 22% upside from current levels, and ACAD's factor scores reinforce the fundamental case: EPS surprise ranks in the 96th percentile, 90-day EPS momentum in the 91st. The valuation is not cheap — the PE has compressed about 3 points over the past month to 34.6x — but the earnings trend has been running ahead of expectations. The bull case rests on NUPLAZID commercial execution and early data from remlifanserin in Alzheimer's psychosis; bears point to DAYBUE's limited growth ceiling and the mixed history of the 5-HT2A mechanism in broader indications.
On the ownership side, Julian C. Baker holds a 25.4% stake under a Schedule 13D filing — meaning he is on record as an activist-intent holder, one of the more consequential structural facts about this name. Baker Bros. Advisors holds another 24.9% of shares as reported by institutional data, making the two Baker-linked entities collectively the dominant force in the register. BlackRock added over 964,000 shares through August, and State Street added 743,000. Insider activity from the CFO in early August was entirely pre-arranged under 10b5-1 plans — routine option exercises followed by matched sales — and carries limited signaling value. The net 90-day insider position is modestly negative at roughly $1.4 million sold, driven by those planned transactions.
Next print is slated for November 4. The week's setup — shorts rebuilding into an ultra-loose borrow market, options hedging picking up modestly, and analysts lifting targets post-earnings — is less about directional conviction from either side and more about what remlifanserin Phase 2 data flow or any DAYBUE commercial update does to resolve the competing narratives heading into that date.
See the live data behind this article on ORTEX.
Open ACAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
